These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30647797)

  • 1. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
    Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
    Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
    Cai Y; Yan X; Zhang G; Zhao W; Jiao S
    Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
    Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
    Dong P; Xu Z; Jia N; Li D; Feng Y
    Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.
    Luo W; Wu F; Elmaoued R; Beck BB; Fischer E; Meng X; Leslie KK; Dai D
    Int J Oncol; 2010 Nov; 37(5):1187-94. PubMed ID: 20878066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
    Miles MA; Harris MA; Hawkins CJ
    Apoptosis; 2019 Jun; 24(5-6):404-413. PubMed ID: 30997620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
    Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
    Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Histone deacetylase inhibitors cause the TP53-dependent induction of p21/Waf1 in tumor cells carrying mutations in TP53].
    Kovalev RA; Shtam TA; Karelov DV; Burdakov VS; Volnitskiy AV; Makarov EM; Filatov MV
    Tsitologiia; 2015; 57(3):204-11. PubMed ID: 26021170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a
    McDonald JI; Diab N; Arthofer E; Hadley M; Kanholm T; Rentia U; Gomez S; Yu A; Grundy EE; Cox O; Topper MJ; Xing X; Strissel PL; Strick R; Wang T; Baylin SB; Chiappinelli KB
    Cancer Res; 2021 Oct; 81(20):5176-5189. PubMed ID: 34433584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
    Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
    Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
    Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
    Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
    J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
    Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
    PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
    Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
    Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
    Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
    Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plakoglobin restores tumor suppressor activity of p53
    Alaee M; Nool K; Pasdar M
    Cancer Sci; 2018 Jun; 109(6):1876-1888. PubMed ID: 29660231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.